Global Oncology Companion Diagnostic Market set to reach $10.60 billion by 2032 with 11.09% CAGR growth
From GlobeNewswire: 2025-02-25 09:45:00
The global Oncology Companion Diagnostic Market was valued at USD 4.12 billion in 2023 and is projected to reach USD 10.60 billion by 2032, with a CAGR of 11.09% from 2024 to 2032. The surge is attributed to personalized medicine and targeted cancer therapies, driving demand for precise diagnostic tools.
Oncology companion diagnostics play a crucial role in personalized cancer treatment by detecting biomarkers and customizing treatments based on genetic makeup. Joint initiatives between pharmaceutical firms and diagnostic developers have fueled market growth, with regulatory authorities simplifying approval procedures for faster therapeutic and diagnostic solutions.
In 2023, the product segment led the oncology companion diagnostics market, while Polymerase Chain Reaction (PCR) dominated the technology segment. Non-Small Cell Lung Cancer (NSCLC) was the leading disease type, with hospitals being the largest end-users. Next-Generation Sequencing (NGS) is expected to grow rapidly, especially in breast cancer diagnostics.
North America led the market in 2023, driven by advanced healthcare infrastructure and regulatory support. The Asia Pacific region is experiencing significant growth due to rising cancer incidence and increased spending on healthcare infrastructure. Recent developments include Roche’s FDA approval for a label expansion of its PATHWAY anti-HER2/neu Rabbit Monoclonal Primary Antibody. Guardant Health has partnered with Boehringer Ingelheim to advance the regulatory approval and commercialization of the Guardant360 CDx liquid biopsy as a companion diagnostic for zongertinib, a treatment for non-small cell lung cancer. This collaboration aims to improve patient outcomes through precision medicine.
The Oncology Companion Diagnostic Market Analysis & Outlook Report for 2024-2032 offers insights into market dynamics, statistical trends, and competitive landscapes. The report covers product and service offerings, technology, disease types, and end-uses in the oncology companion diagnostic market. Customized research inquiries are also available for tailored market insights.
SNS Insider, a leading market research agency, provides clients with up-to-date market data, consumer insights, and opinions to make informed decisions confidently. Through surveys, video talks, and focus groups globally, SNS Insider aims to deliver accurate information for clients to navigate changing market dynamics effectively.
Read more at GlobeNewswire: Oncology Companion Diagnostic Market Size to Hit USD 10.60